Tau and S100B Proteins as Biochemical Markers of Bilirubin-Induced Neurotoxicity in Term Neonates

Pediatric Neurology

Volumn 39, Issue 4, 2008, Pages 245-252

  Okumus, Nurullah ^a   Turkyilmaz, Canan ^a   Onal, Eray Esra ^a   Atalay, Yildiz ^a   Serdaroglu, Ayse ^a   Elbeg, Sehri ^a   Koc, Esin ^a   Deda, Gulhis ^b   Cansu, Ali ^a   Gunduz, Bulent ^a  

^a GAZI UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BIOCHEMICAL MARKER; PROTEIN S100B; TAU PROTEIN;

ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ASSESSMENT; ELECTROENCEPHALOGRAM; EVOKED BRAIN STEM AUDITORY RESPONSE; FEMALE; HUMAN; JAUNDICE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NEWBORN; NEWBORN JAUNDICE; OTOACOUSTIC EMISSION; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VESTIBULOCOCHLEAR NERVE DISEASE;

BILIRUBIN; BIOLOGICAL MARKERS; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; HUMANS; HYPERBILIRUBINEMIA; INFANT; INFANT, NEWBORN; JAUNDICE, NEONATAL; KERNICTERUS; NERVE GROWTH FACTORS; OTOACOUSTIC EMISSIONS, SPONTANEOUS; S100 PROTEINS; TAU PROTEINS;

EID: 52049111617     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2008.07.004     Document Type: Article

References (55)

1. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn i{dotless}nfant 35 or more weeks of gestation. Pediatrics 114 (2004) 297-316
2. Newman T.B., and Maisels M.J. Magnetic resonance imaging and kernicterus. Pediatrics 109 (2002) 555
3. Nakamura H., Takada S., Shimabuku R., Matsuo M., Matsuo T., and Negishi H. Auditory nerve and brainstem responses in newborn infants with hyperbilirubinemia. Pediatrics 75 (1985) 703-708
4. Streletz L.J., Graziani L.J., Branca P.A., Desai H.J., Travis S.F., and Mikaelian D.O. Brainstem auditory evoked potentials in fullterm and preterm newborns with hyperbilirubinemia and hypoxemia. Neuropediatrics 17 (1986) 66-71
5. Gupta A.K., Raj H., and Anand N.K. Auditory brainstem responses (ABR) in neonates with hyperbilirubinemia. Indian J Pediatr 57 (1990) 705-711
6. Shapiro S.M. Definition of the clinical spectrum of kernicterus and bilirubin-induced neurological dysfunction (BIND). J Perinatol 25 (2005) 54-59
7. Brito M.A., Brites D., and Butterfield D.A. A link between hyperbilirubinemia, oxidative stress and injury to neocortical synaptosomes. Brain Res 1026 (2004) 33-43
8. Ostrow J.D., Pascolo L., Brites D., and Tiribelli C. Molecular basis of bilirubin-induced neurotoxicity. Trends Mol Med 10 (2004) 65-70
9. Silva R.F., Rodrigues C.M., and Brites D. Rat cultured neuronal and glial cells respond differently to toxicity of unconjugated bilirubin. Pediatr Res 51 (2002) 535-541
10. Ostrow J.D., Pascolo L., and Tiribelli C. Reassessment of the unbound concentrations of unconjugated bilirubin in relation to neurotoxicity in vitro. Pediatr Res 54 (2003) 98-104
11. Goedert M., Crowther R.A., and Garner C.C. Molecular characterization of microtubule associated proteins Tau and MAP2. Trends Neurosci 14 (1991) 193-199
12. Spillantini M.G., and Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci 21 (1998) 428-433
13. Joshi H.C. Microtubule dynamics in living cells. Curr Opin Cell Biol 10 (1998) 35-44
14. Lindwall G., and Cole R.D. Phosphorylation affects the ability of Tau protein to promote microtubule assembly. J Biol Chem 259 (1984) 5301-5305
15. Zemlan F.P., Rosenberg W.S., Luebbe P.A., et al. Quantification of axonal damage in traumatic brain injury: Affinity purification and characterization of cerebrospinal fluid Tau proteins. J Neurochem 72 (1999) 741-750
16. Johnson G.V., and Jenkins S.M. Tau protein in normal and Alzheimer's disease brain. J Alzheimers Dis 1 (1999) 307-328
17. Tapiola T., Soininen H., and Pirttila T. CSF Tau and Abeta42 levels in patients with Down's syndrome. Neurology 10; (2001) 56 979-80
18. Van Gool S.W., Van Kerschaver E., Brock P., et al. Disease- and treatment-related elevation of the neurodegenerative marker Tau in children with hematological malignancies. Leukemia 14 (2000) 2076-2084
19. Van Droogenbroeck P., De Jongh R., Kenis G., Vundelinckx G., Monstrey J., and Heylen R. Tau in serum and CSF during cerebral injury. Crit Care 1 Suppl. 1 (1997) P11
20. Andreasen N., Vanmechelen E., Van de Voorde A., et al. Cerebrospinal fluid Tau protein as a biochemical marker for Alzheimer's disease: A community based follow up study. J Neurol Neurosurg Psychiatry 64 (1998) 298-305
21. Zimmer D.B., Cornwall E.H., Landar A., and Song W. The S100 protein family: History, function, and expression. Brain Res Bull 37 (1995) 417-429
22. Van Eldik L.J., and Wainwright M.S. The Janus face of glial-derived S100B: Beneficial and detrimental functions in the brain. Restor Neurol Neurosci 21 (2003) 97-108
23. Rothermundt M., Peters M., Prehn J.H., and Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech 60 (2003) 614-632
24. Leviton A., and Dammann O. Brain damage markers in children. Neurobiological and clinical aspects. Acta Paediatr Scand 91 (2002) 9-13
25. Gazzolo D., Vinesi P., Bartocci M., et al. Elevated S100 blood level as an early indicator of intraventricular hemorrhage in preterm infants. Correlation with cerebral Doppler velocimetry. J Neurol Sci 170 (1999) 32-35
26. Nagdyman N., Kömen W., Ko H.K., Müller C., and Obladen M. Early biochemical indicators of hypoxic-ischemic encephalopathy after birth asphyxia. Pediatr Res 49 (2001) 502-506
27. Thorngren-Jerneck K., and Alling C. S-100 in term newborn infants with hypoxic ischemic encephalopathy after birth asphyxia. J Neurochem 73 Suppl. (1999) S198
28. Maschmann J., Erb M.A., Heinemann M.K., Ziemer G., and Speer C.P. Evaluation of protein S-100 serum concentrations in healthy newborns and seven newborns with perinatal acidosis. Acta Paediatr Scand 89 (2000) 553-555
29. Bierman-van Eendenburg M.E., Jurgens-van der Zee A.D., Olinga A.A., Huisjes H.H., and Touwen B.C. Predictive value of neonatal neurological examination: A follow-up study at 18 months. Dev Med Child Neurol 23 (1981) 296-305
30. Bray P., and Kemp D. An advanced cochlear echo technique suitable for infant screening. Br J Audiol 21 (1987) 191-204
31. Starr A., Picton T.W., Sininger Y., Hood L.J., and Berlin C.I. Auditory neuropathy. Brain 119 (1996) 741-753
32. Deltenre P., Mansbach A.L., Bozet C., Clercx A., and Hecox K.E. Auditory neuropathy: A report on three cases with early onsets and major neonatal illnesses. Electroencephalogr Clin Neurophysiol 104 (1997) 17-22
33. Psarommatis I., Riga M., Douros K., et al. Transient infantile auditory neuropathy and its clinical implications. Int J Pediatr Otorhinolaryngol 70 (2006) 1629-1637
34. Chisin R., Perlman M., and Sohmer H. Cochlear and brain stem responses in hearing loss following neonatal hyperbilirubinemia. Ann Otol Rhinol Laryngol 88 (1979) 352-357
35. Shapiro S.M., and Nakamura H. Bilirubin and the auditory system. J Perinatol 21 Suppl. 1 (2001) S52-S55
36. AAP Subcommittee on Neonatal Hyperbilirubinemia. Neonatal jaundice and kernicterus. Pediatrics 108 (2001) 763-765
37. Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia, American Academy of Pediatrics. Practice parameter: Management of hyperbilirubinemia in the healthy term newborn. Pediatrics 94 (1994) 558-565
38. Mollison P.L., and Cutbush M. A method for measuring the severity of a series of cases of hemolytic disease of the newborn. Blood 6 (1951) 777-788
39. Hsia D.Y., Allen F.H., Gellis S.S., and Diamond L.K. Erythroblastosis fetalis. VIII. Studies of serum bilirubin in relation to kernicterus. N Engl J Med 247 (1952) 668-671
40. Hsia D.Y., and Gellis S.S. Studies on erythroblastosis due to ABO incompatibility. Pediatrics 13 (1954) 503-510
41. Brown A.K. Kernicterus: Past, present and future. Neoreviews 4 (2003) 33-40
42. Newman T.B., and Maisels M.J. Evaluation and treatment of jaundice in the term newborn: A kinder, gentler approach. Pediatrics 89 (1992) 809-818
43. Valaes T. Bilirubin toxicity: The problem was solved a generation ago. Pediatrics (1999) 819-821
44. Hansen T.W. Kernicterus in term and near-term infants-The specter walks again. Acta Paediatr Scand 89 (2000) 1155-1157
45. Watchko J.F. Recurrence of kernicterus in term and near-term infants in Denmark. Acta Paediatr Scand 90 (2001) 1080
46. Ip S., Chung M., Kulig J., et al. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics 114 (2004) 130-153
47. Braveman P., Egerter S., Pearl M., Marchi K., and Miller C. Problems associated with early discharge of newborn infants. Early discharge of newborns and mothers: A critical review of the literature. Pediatrics 96 (1995) 716-726
48. Britton J.R., Britton H.L., and Beebe S.A. Early discharge of the term newborn: A continued dilemma. Pediatrics 94 (1994) 291-295
49. Catz C., Hanson J.W., Simpson L., and Yaffe S.J. Summary of workshop: Early discharge and neonatal hyperbilirubinemia. Pediatrics 96 (1995) 743-745
50. Seidman D., Stevenson D.K., Ergaz Z., and Gale R. Hospital readmission due to neonatal hyperbilirubinemia. Pediatrics 96 (1995) 727-729
51. Newman T.B., and Klebanoff M.A. Neonatal hyperbilirubinemia and long-term outcome: Another look at the collaborative perinatal project. Pediatrics 92 (1993) 651-657
52. Grimmer I., Berger-Jones K., Bührer C., Brandl U., and Obladen M. Late neurological sequela of non-hemolytic hyperbilirubinemia of healthy term neonates. Acta Paediatr Scand 88 (1999) 661-663
53. Ozmert E., Erdem G., Topcu M., et al. Long-term follow-up of indirect hyperbilirubinemia in full-term Turkish infants. Acta Paediatr Scand 85 (1996) 1440-1444
54. Newman T.B., and Maisels M.J. Does hyperbilirubinemia damage the brain of healthy full-term infants?. Clin Perinatol 17 (1990) 331-358
55. Newman T.B., Liljestrand P., Jeremy R.J., et al. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med 354 (2006) 1889-1900